Responses of tumors induced in inbred guinea pig strain JY=1 and strain Hartley/F to BCG.
A transplantable fibrosarcoma induced in inbred JY-1 guinea pig strain by 3-methylcholanthrene (MCA) and designated J4, an allotransplantable subline of J4 (JH4) which was obtained by the transplantation of J4 into the inbred Hartley/F guinea pig strain and maintained by passages in this strain, and a syngeneic liposarcoma H10 induced in a Hartley/F guinea pig by MCA were tested for their immunotherapeutic response with BCG. The growth of J4 and H10 tumors was suppressed in most of the animals when tumor cells were mixed with BCG before being injected sc into BCG-immune or BCG-nonimmune recipients. The growth of the JH4 tumor was suppressed at the sites of injection with a mixture of tumor cells and BCG in BCG-immune recipients but not in nonimmune animals. All guinea pigs surviving the injection of a tumor cell-BCG mixture resisted a second tumor cell challenge. When subcutaneous sarcomas grew to about 8-15 mm in diameter, BCG was injected into the tumors. The growth of JH4 tumor was not influenced by the injection in either BCG-immune or BCG-nonimmune animals, while the regression of the established J4 transplants was produced in 2 of 3 nonimmune recipients. The growth of the H10 tumor was not inhibited with an intratumor injection into nonimmune guinea pigs, while the H10 tumor regressed in BCG-immune animals for 4-5 weeks after intratumor injection and thereafter grew progressively. Skin reactions in animals that received repeated intradermal injections of the tumor cells and BCG were tested with 10(6) viable tumor cells as eliciting antigens. Typical delayed-type hypersensitivity reactions that were specific to the homologous antigens were observed. The possible reasons for the different responses to BCG among the guinea pig tumors, including line-10 hepatocarcinoma in strain-2 guinea pigs, were discussed.
D000818:Animals; D000951:Antigens, Neoplasm; D001500:BCG Vaccine; D005354:Fibrosarcoma / Q000139:chemically induced / Q000473:pathology / Q000628:therapy*; D006084:Graft Rejection; D006168:Guinea Pigs; D007109:Immunity; D007167:Immunotherapy; D008080:Liposarcoma / Q000139:chemically induced / Q000473:pathology / Q000628:therapy*; D008297:Male; D008748:Methylcholanthrene; D009163:Mycobacterium bovis / Q000276:immunology*; D009368:Neoplasm Transplantation; D012513:Sarcoma, Experimental / Q000139:chemically induced / Q000473:pathology / Q000628:therapy; D014184:Transplantation, Homologous; D014185:Transplantation, Isogeneic
D000951:Antigens, Neoplasm; D001500:BCG Vaccine; D008748:Methylcholanthrene